Hansoh Pharma (03692): The second application for the market authorization of Xinyue (Inolimomab monoclonal antibody injection) has been accepted by the National Medical Products Administration.

Hansoh Pharma (03692) announced that on March 4, 2025, the second Biologics License Application (BLA) for the innovative drug Xinyue (Enalizumab injection) has been accepted by the National Medical Products Administration (NMPA) for the treatment of Immunoglobulin G4-related diseases (IgG4-RD). On February 8, 2025, this indication was granted priority review and approval by the NMPA.